|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Blandin Knight S, Crosbie PA, Balata H,
Chudziak J, Hussell T and Dive C: Progress and prospects of early
detection in lung cancer. Open Biol. 7:1700702017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Akamatsu H, Mori K, Naito T, Imai H, Ono
A, Shukuya T, Taira T, Kenmotsu H, Murakami H, Endo M, et al:
Progression-free survival at 2 years is a reliable surrogate marker
for the 5-year survival rate in patients with locally advanced
non-small cell lung cancer treated with chemoradiotherapy. BMC
Cancer. 14:182014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Allemani C, Matsuda T, Di Carlo V,
Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ,
Estève J, et al: Global surveillance of trends in cancer survival
2000–14 (CONCORD-3): Analysis of individual records for 37 513 025
patients diagnosed with one of 18 cancers from 322 population-based
registries in 71 countries. Lancet. 391:1023–1075. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fennell DA, Summers Y, Cadranel J, Benepal
T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C and Ferry
D: Cisplatin in the modern era: The backbone of first-line
chemotherapy for non-small cell lung cancer. Cancer Treat Rev.
44:42–50. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brückl W, Tufman A and Huber RM: Advanced
non-small cell lung cancer (NSCLC) with activating EGFR mutations:
First-line treatment with afatinib and other EGFR TKIs. Expert Rev
Anticancer Ther. 17:143–155. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu WJ, Peng W, Sun QQ, Li YH, Chen B, Yu
LT, Xu YZ, Wang SY and Zhao YL: #2714, a novel active inhibitor
with potent arrested G2/M phase and antitumor efficacy in
preclinical models. Cell Death Discov. 4:242018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu YZ, Zheng RL, Zhou Y, Peng F, Lin HJ,
Bu Q, Mao YQ, Yu LT, Yang L and Yang SY: Small molecular anticancer
agent SKLB703 induces apoptosis in human hepatocellular carcinoma
cells via the mitochondrial apoptotic pathway in vitro and inhibits
tumor growth in vivo. Cancer Lett. 313:44–53. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi
Y, Vande Woude GF and Testa JR: Anti-apoptotic signaling by
hepatocyte growth factor/Met via the phosphatidylinositol
3-kinase/Akt and mitogen-activated protein kinase pathways. Proc
Natl Acad Sci USA. 98:247–252. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Downward J: Use of RNA interference
libraries to investigate oncogenic signalling in mammalian cells.
Oncogene. 23:8376–8383. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li P, Nijhawan D, Budihardjo I,
Srinivasula SM, Ahmad M, Alnemri ES and Wang X: Cytochrome c and
dATP-dependent formation of Apaf-1/caspase-9 complex initiates an
apoptotic protease cascade. Cell. 91:479–489. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Printz C: Targeted therapy in lung cancer:
Survival, quality of life improved for some patients. Cancer.
120:2625–2626. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ramalingam SS, Blackhall F, Krzakowski M,
Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank
R, et al: Randomized phase II study of dacomitinib (PF-00299804),
an irreversible pan-human epidermal growth factor receptor
inhibitor, versus erlotinib in patients with advanced
non-small-cell lung cancer. J Clin Oncol. 30:3337–3344. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hartmann JT, Haap M, Kopp HG and Lipp HP:
Tyrosine kinase inhibitors-a review on pharmacology, metabolism and
side effects. Curr Drug Metab. 10:470–481. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Anastas JN and Moon RT: WNT signalling
pathways as therapeutic targets in cancer. Nat Rev Cancer.
13:11–26. 2012. View
Article : Google Scholar
|
|
16
|
Brown K, Yang P, Salvador D, Kulikauskas
R, Ruoholabaker H, Robitaille AM, Chien AJ, Moon RT and Sherwood V:
WNT/β-catenin signaling regulates mitochondrial activity to alter
the oncogenic potential of melanoma in a PTEN-dependent manner.
Oncogene. 36:3119–3136. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Regmi SC, Park SY, Kim SJ, Banskota S,
Shah S, Kim DH and Kim JA: The anti-tumor activity of Succinyl
Macrolactin A is mediated through the β-catenin destruction complex
via the suppression of tankyrase and PI3K/Akt. PLoS One.
10:e01417532015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhan T, Rindtorff N and Boutros M: Wnt
signaling in cancer. Oncogene. 36:1461–1473. 2018. View Article : Google Scholar
|
|
19
|
Clevers H and Nusse R: Wnt/β-catenin
signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Akiri G, Cherian MM, Vijayakumar S, Liu G,
Bafico A and Aaronson SA: Wnt pathway aberrations including
autocrine Wnt activation occur at high frequency in human
non-small-cell lung carcinoma. Oncogene. 28:2163–2172. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kreuzaler P and Watson CJ: Killing a
cancer: What are the alternatives? Nat Rev Cancer. 12:411–424.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shalini S, Dorstyn L, Dawar S and Kumar S:
Old, new and emerging functions of caspases. Cell Death Differ.
22:526–539. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pradelli LA, Bénéteau M and Ricci JE:
Mitochondrial control of caspase-dependent and -independent cell
death. Cell Mol Life Sci. 67:1589–1597. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Denisenko TV, Budkevich IN and Zhivotovsky
B: Cell death-based treatment of lung adenocarcinoma. Cell Death
Dis. 9:1172018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Brentnall M, Rodriguez-Menocal L, De
Guevara RL, Cepero E and Boise LH: Caspase-9, caspase- 3 and
caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell
Biol. 14:322013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Azmi AS, Wang Z, Philip PA, Mohammad RM
and Sarkar FH: Emerging Bcl-2 inhibitors for the treatment of
cancer. Expert Opin Emerg Drugs. 16:59–70. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wells A, Grahovac J, Wheeler S, Ma B and
Lauffenburger D: Targeting tumor cell motility as a strategy
against invasion and metastasis. Trends Pharmacol Sci. 34:283–289.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu YZ, Li YH, Lu WJ, Lu K, Wang CT, Li Y,
Lin HJ, Kan LX, Yang SY, Wang SY and Zhao YL: YL4073 is a potent
autophagy-stimulating antitumor agent in an in vivo model of
Lewis lung carcinoma. Oncol Rep. 35:2081–2088. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu Y, Lu W, Yang P, Peng W, Wang C, Li M,
Li Y, Li G, Meng N, Lin H, et al: A small molecular agent YL529
inhibits VEGF-D-induced lymphangiogenesis and metastasis in
preclinical tumor models in addition to its known antitumor
activities. BMC Cancer. 15:5252015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zheng RL, Zeng XX, He HY, He J, Yang SY,
Yu YT and Yang L: Facile synthesis of
6-Aryl-3-cyanopyridine-2-(1H)-thiones from Aryl Ketones. J
Synthetic Commun. 42:1521–1531. 2012. View Article : Google Scholar
|
|
31
|
Kilkenny C, Browne W, Cuthill IC, Emerson
M and Altman DG; NC3Rs Reporting Guidelines Working Group, : Animal
research: Reporting in vivo experiments: The ARRIVE guidelines. J
Physiol. 160:1577–1579. 2010.
|
|
32
|
Mitrofanova A, Aytes A, Zou M, Shen MM,
Abate-Shen C and Califano A: Predicting drug response in human
prostate cancer from preclinical analysis of in vivo mouse models.
Cell Rep. 12:2060–2071. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Awazu Y, Nakamura K, Mizutani A, Kakoi Y,
Iwata H, Yamasaki S, Miyamoto N, Imamura S, Miki H and Hori A: A
novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a
broad spectrum of in vivo antitumor activities. Mol Cancer Ther.
12:913–924. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Niehrs C: The complex world of WNT
receptor signalling. Nat Rev Mol Cell Biol. 13:767–779. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Villanueva MT: Targeted therapies: Priming
apoptosis. Nat Rev Clin Oncol. 10:672013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sarosiek KA, Fraser C, Muthalagu N, BholaP
D, Chang WT, McBrayer SK, Cantlon A, Fisch S, Golomb-Mello G, Ryan
JA, et al: Developmental regulation of mitochondrial apoptosis by
c-Myc governs age- and tissue-specific sensitivity to cancer
therapeutics. Cancer Cell. 31:142–156. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fulda S: The PI3K/Akt/mTOR pathway as
therapeutic target in neuroblastoma. Curr Cancer Drug Targets.
9:729–737. 2014. View Article : Google Scholar
|
|
38
|
Davidson SM, Lopaschuk GD, Spedding M and
Beart PM: Mitochondrial pharmacology: Energy, injury and beyond. Br
J Pharmacol. 171:1795–1797. 2014. View Article : Google Scholar : PubMed/NCBI
|
